Long-term outcomes after extracorporeal membrane oxygenation in patients with dialysis-requiring acute kidney injury: A cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
09
2018
accepted:
31
01
2019
entrez:
14
3
2019
pubmed:
14
3
2019
medline:
26
11
2019
Statut:
epublish
Résumé
Acute kidney injury (AKI) is a common complication of extracorporeal membrane oxygenation (ECMO) treatment. The aim of this study was to elucidate the long-term outcomes of adult patients with AKI who receive ECMO. The study analyzed encrypted datasets from Taiwan's National Health Insurance Research Database. The data of 3251 patients who received first-time ECMO treatment between January 1, 2003, and December 31, 2013, were analyzed. Characteristics and outcomes were compared between patients who required dialysis for AKI (D-AKI) and those who did not in order to evaluate the impact of D-AKI on long-term mortality and major adverse kidney events. Of the 3251 patients, 54.1% had D-AKI. Compared with the patients without D-AKI, those with D-AKI had higher rates of all-cause mortality (52.3% vs. 33.3%; adjusted hazard ratio [aHR] 1.82, 95% confidence interval [CI] 1.53-2.17), chronic kidney disease (13.7% vs. 8.1%; adjusted subdistribution HR [aSHR] 1.66, 95% CI 1.16-2.38), and end-stage renal disease (5.2% vs. 0.5%; aSHR 14.28, 95% CI 4.67-43.62). The long-term mortality of patients who survived more than 90 days after discharge was 22.0% (153/695), 32.3% (91/282), and 50.0% (10/20) in the patients without D-AKI, with recovery D-AKI, and with nonrecovery D-AKI who required long-term dialysis, respectively, demonstrating a significant trend (Pfor trend <0.001). AKI is associated with an increased risk of long-term mortality and major adverse kidney events in adult patients who receive ECMO.
Sections du résumé
BACKGROUND
Acute kidney injury (AKI) is a common complication of extracorporeal membrane oxygenation (ECMO) treatment. The aim of this study was to elucidate the long-term outcomes of adult patients with AKI who receive ECMO.
MATERIALS AND METHODS
The study analyzed encrypted datasets from Taiwan's National Health Insurance Research Database. The data of 3251 patients who received first-time ECMO treatment between January 1, 2003, and December 31, 2013, were analyzed. Characteristics and outcomes were compared between patients who required dialysis for AKI (D-AKI) and those who did not in order to evaluate the impact of D-AKI on long-term mortality and major adverse kidney events.
RESULTS
Of the 3251 patients, 54.1% had D-AKI. Compared with the patients without D-AKI, those with D-AKI had higher rates of all-cause mortality (52.3% vs. 33.3%; adjusted hazard ratio [aHR] 1.82, 95% confidence interval [CI] 1.53-2.17), chronic kidney disease (13.7% vs. 8.1%; adjusted subdistribution HR [aSHR] 1.66, 95% CI 1.16-2.38), and end-stage renal disease (5.2% vs. 0.5%; aSHR 14.28, 95% CI 4.67-43.62). The long-term mortality of patients who survived more than 90 days after discharge was 22.0% (153/695), 32.3% (91/282), and 50.0% (10/20) in the patients without D-AKI, with recovery D-AKI, and with nonrecovery D-AKI who required long-term dialysis, respectively, demonstrating a significant trend (Pfor trend <0.001).
CONCLUSION
AKI is associated with an increased risk of long-term mortality and major adverse kidney events in adult patients who receive ECMO.
Identifiants
pubmed: 30865662
doi: 10.1371/journal.pone.0212352
pii: PONE-D-18-28184
pmc: PMC6415889
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0212352Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Medicine (Baltimore). 2015 Nov;94(45):e2025
pubmed: 26559305
Clin J Am Soc Nephrol. 2015 Mar 6;10(3):353-62
pubmed: 25527706
Clin J Am Soc Nephrol. 2006 Jan;1(1):43-51
pubmed: 17699189
Perfusion. 2018 Jul;33(5):375-382
pubmed: 29360002
Int J Cardiol. 2015 Dec 15;201:96-101
pubmed: 26292275
Circulation. 2016 Jun 14;133(24):2423-33
pubmed: 27199466
Clin Nephrol. 2016 Jan;85(1):1-11
pubmed: 26636328
Pediatr Crit Care Med. 2017 Dec;18(12):1126-1135
pubmed: 28937504
Cardiorenal Med. 2015 Jun;5(3):157-63
pubmed: 26195967
Clin J Am Soc Nephrol. 2012 May;7(5):844-50
pubmed: 22442182
Clin J Am Soc Nephrol. 2014 Mar;9(3):448-56
pubmed: 24311708
Am J Kidney Dis. 2017 Jan;69(1):18-28
pubmed: 27555107
J Card Surg. 2016 Apr;31(4):248-52
pubmed: 26842109
Medicine (Baltimore). 2015 Oct;94(40):e1703
pubmed: 26448023
Nephron. 2015;131(2):102-6
pubmed: 26340262
J Formos Med Assoc. 2017 Nov;116(11):844-851
pubmed: 28874330
Artif Organs. 2016 Aug;40(8):746-54
pubmed: 27139839
Medicine (Baltimore). 2016 Feb;95(8):e2870
pubmed: 26937920
Intensive Care Med. 2014 Sep;40(9):1256-66
pubmed: 24934814
Crit Care. 2013 Oct 11;17(5):R231
pubmed: 24119576
Clin J Am Soc Nephrol. 2012 May;7(5):856-60
pubmed: 22442184
JAMA. 2012 Nov 14;308(18):1906-14
pubmed: 23162861
Crit Care. 2016 Aug 12;20(1):256
pubmed: 27520553
Ann Thorac Surg. 2015 Oct;100(4):1485-95
pubmed: 26341602
Am J Kidney Dis. 2016 May;67(5):742-52
pubmed: 26690912
Crit Care. 2017 Sep 26;21(1):245
pubmed: 28946897
J Am Soc Nephrol. 2014 Mar;25(3):595-605
pubmed: 24503241
Kidney Int. 2012 Mar;81(5):442-8
pubmed: 22113526
Cardiorenal Med. 2015 Dec;6(1):50-60
pubmed: 27194996
Crit Care Med. 2015 May;43(5):1016-25
pubmed: 25738858
Heart Lung Circ. 2014 Apr;23(4):363-8
pubmed: 24219845
J Am Soc Nephrol. 2016 Jun;27(6):1854-60
pubmed: 26487562
Crit Care. 2016 Aug 03;20(1):242
pubmed: 27488839
J Formos Med Assoc. 2014 Nov;113(11):778-85
pubmed: 24928419
J Crit Care. 2015 Oct;30(5):949-56
pubmed: 26111916
Am J Nephrol. 2017;46(2):139-149
pubmed: 28738354
PLoS One. 2018 Sep 4;13(9):e0203447
pubmed: 30180211
Nephrol Dial Transplant. 2013 Jan;28(1):86-90
pubmed: 23136216
J Thorac Cardiovasc Surg. 2017 Aug;154(2):469-477.e2
pubmed: 28413074
Kidney Int Suppl. 1997 Dec;63:S124-7
pubmed: 9407439